| Literature DB >> 17483100 |
Thomas H McGlashan1, Jean Addington, Tyrone Cannon, Markus Heinimaa, Patrick McGorry, Mary O'Brien, David Penn, Diana Perkins, Raimo K R Salokangas, Barbara Walsh, Scott W Woods, Alison Yung.
Abstract
The prodrome of psychosis has become a target for early identification and for treatments that address both symptoms and risk for future psychosis. Interest and activity in this realm is now worldwide. Clinical trials with rigorous methodology have only just begun, making treatment guidelines premature. Despite the sparse evidence base, treatments are currently applied to patients in the new prodromal clinics, usually treatments developed for established psychosis and modified for the prodromal phase. This communication will describe representative samplings of how treatment-seeking prodromal patients are currently recruited and treated in prodromal clinics worldwide. Recruitment includes how prodromal patients are sought, initially evaluated, apprised of their high-risk status, and informed of the risks and benefits of prodromal treatments and how their mental state is monitored over time. The treatment modalities offered (and described) include engagement, supportive therapy, case management, stress management, cognitive behavioral treatment, family-based treatment, antipsychotic pharmacotherapy, and non-antipsychotic pharmacotherapy. References for details are noted.Entities:
Mesh:
Year: 2007 PMID: 17483100 PMCID: PMC2526155 DOI: 10.1093/schbul/sbm025
Source DB: PubMed Journal: Schizophr Bull ISSN: 0586-7614 Impact factor: 9.306